Support legislation that invests $10 billion in scientific research over ten years to accelerate cancer cures, rare disease treatments, and diagnostics and vaccines for emerging threats.

So I support legislation that would invest $10 billion in scientific research over the next ten years and foster partnerships between government and the private sector to accelerate progress towards a cure for cancer, treatments for rare diseases, and diagnostics and vaccines for emerging threats like COVID-19.

Commits to supporting a major research investment and related public-private partnerships.

Chrissy Houlahan For U.S. Congress
campaign · campaign_site · model gpt-5.4-mini

The BIOTech Caucus, co-chaired by Houlahan, announced its first endorsed bills. One endorsed bill was the Biomanufacturing Excellence Act (H.R. 6089), which would create a national biopharmaceutical manufacturing center of excellence to strengthen domestic manufacturing, accelerate innovation, and train the workforce.

Recent official evidence that Houlahan continued to back biotechnology legislation aimed at accelerating innovation and domestic biopharmaceutical capacity, but not the specific $10 billion cancer/rare-disease/emerging-threat funding pledge.

unresolved same_term A for effort

Co-Chairs Houlahan, Bice Announce First BIOTech Caucus Legislative Endorsements | U.S. Representative Chrissy Houlahan
secondary · model gpt-5.4-mini · confidence 82%

Houlahan introduced the Biomanufacturing Excellence Act, saying the bill would promote U.S. leadership in biotechnology and strengthen domestic biopharmaceutical manufacturing, including collaborative research on scaling production.

Shows Houlahan actively sponsoring biotech legislation consistent with the broader promise, but it does not establish enactment or the specific $10 billion research investment promised.

unresolved same_term A for effort

Houlahan introduces legislation to strengthen biopharmaceutical manufacturing | U.S. Representative Chrissy Houlahan
secondary · model gpt-5.4-mini · confidence 80%

Houlahan announced that key provisions from her RAMP for Innovators Act were included in the final SBIR/STTR reauthorization package, which strengthens federal support for innovation and commercialization and was headed to the President's desk.

Concrete, official evidence that Houlahan was securing pro-innovation federal policy in the same general space, but it is not the claimed $10 billion research investment or a direct cancer/rare-disease funding measure.

partial same_term A for effort

Houlahan Secures Key Provisions of Bipartisan Innovation Bill in Final SBIR/STTR Package | U.S. Representative Chrissy Houlahan
secondary · model gpt-5.4-mini · confidence 71%